Medtronic 2016 Annual Report Download - page 49

Download and view the complete annual report

Please find page 49 of the 2016 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 158

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158

Table of Contents
46
• Changes in procedural volumes, competitive pressure, reimbursement challenges, reprocessed products,
impacts from changes in the mix of our product offerings, fluctuations in currency exchange rates and pricing
pressure, particularly in developed markets.
• Our ability to create markets and drive product and procedures into emerging markets. We have high quality
and cost-effective surgical products designed for customers in emerging markets such as the ReliaMax reusable
stapler, which is reposable (part reusable, part disposable), and the ValleyLab LS10 single channel vessel sealing
generator, which is compatible with our line of LigaSure instruments and designed for simplified use and
affordability.
• Continued acceptance and future growth within the end stage renal disease market. The population of patients
treated for end stage renal disease globally is expected to double over the next decade. We will grow our therapy
innovation with scalable and affordable dialysis delivery and investing in vascular creation and maintenance
technologies. Our ability to successfully integrate Bellco into Medtronic. Bellco is a pioneer in hemodialysis
treatment solutions that we acquired in February 2016.
• Continued growth due to cross-selling initiatives of Minimally Invasive Therapies Group within other
businesses with Medtronic.
• Continued elevation of the standard of care for respiratory compromise, a progressive condition impacting a
patient’s ability to breathe effectively. The Capnostream35 is expected to launch in fiscal year 2017.
• Creation of less invasive standards of care in diseases and conditions of the gastrointestinal tract and lung to
enable earlier diagnosis and intervention.
• Continued and future acceptance of advanced and general surgical care products from both physicians and
patients of open and minimally invasive procedures in Surgical Solutions, including stapling, vessel sealing,
and other surgical instruments.
• Expanding the use of less invasive treatments and furthering our commitment to improving options for women
with abnormal uterine bleeding with the fiscal year 2017 acquisition of a highly profitable and fast-growing
gynecology business. The addition will expand and strengthen the Minimally Invasive Therapies Group’s
offerings and complement the existing global gynecology business.
• Ability to develop a surgical robotic platform that reduces the variability of surgical procedures and improves
the repeatability and reliability of procedures
• Continued acceptance of other recently launched products including the Endo GIA Reinforced Reload, the
LigaSure Maryland jaw laparoscopic sealer and divider, and three additional sizes of the Sonicision Cordless
Ultrasonic Dissection Device and the GastriSail Gastric Positioning System.
• Future acceptance of the Signia Stapling System, expected to launch in fiscal year 2017. The single-hand use
increases patient focus and consistent staple lines reduce leaks and tissue trauma.
• Future acceptance of the HD multi-pass system, expected to launch in fiscal year 2018. The HD multi-pass
system reduces infrastructure by requiring less water, has less start-up costs, and offers high quality ultrapure
dialysate treatment.
• Continued acceptance and growth in respiratory care, ventilation and airway management, patient monitoring,
and homecare. Key products in this area include the Puritan Bennett 980 ventilator, Microstream Capnography
bedside capnography monitor, portable monitor with Nellcor pulse oximetry system with OxiMax technology
and the Nellcor Respiratory Compromise monitor with vital signs of SpO2, pulse rate, End-Tidal CO2, and
Respiratory Rate.
• Continued and future acceptance of Early Technologies, including the areas of GI solutions, advanced ablation,
and interventional lung solutions. Recently launched products include the PillCam COLON capsule endoscopy,
Emprint ablation system with Thermosphere Technology which maintains predictable spherical ablation zones
throughout procedures reducing procedure time and cost, and the GenCut core biopsy system and the
superDimension Triple Needle Cytology Brush, lung tissue biopsy tools for use with the superDimension
navigation system. The superDimension system enables a minimally invasive approach to accessing difficult-
to-reach areas of the lung, which can aid in the diagnosis of lung cancer.